Abstract
Most of the people suffering malaria do not know how complex is that disease and how hard searchers are working to fight against it. Some of these people are dying from malaria while still efficient drug combinations should have save their lives. But these drugs were not available for them when needed, or the diagnosis was wrong, or the drugs were fake, or the doctor was untrained, or the patient had no money. Should this terrible reality preclude the need for continuous research to develop new antimalarial drugs? Should people working in laboratories located in non-endemic countries adapt their project to that reality? Malaria eradication, then elimination was announced and broadcasted in the late sixties, and later forgotten. From that failure due to chloroquine resistance and after decades of less arrogant work, billions of dollars are on the table again to claim this goal. There were bed nets, drugs, vaccine and communication as starters, let’s hope people in endemic countries will be winners.
Keywords: Antimalarial drugs, chemistry, disease, dogma, endemic areas, malaria, patients, plasmodium.
Current Topics in Medicinal Chemistry
Title:New Anti-Malarial Drugs: Who Cares?
Volume: 14 Issue: 14
Author(s): Stephane Picot, Philippe M. Loiseau and Anne-Lise Bienvenu
Affiliation:
Keywords: Antimalarial drugs, chemistry, disease, dogma, endemic areas, malaria, patients, plasmodium.
Abstract: Most of the people suffering malaria do not know how complex is that disease and how hard searchers are working to fight against it. Some of these people are dying from malaria while still efficient drug combinations should have save their lives. But these drugs were not available for them when needed, or the diagnosis was wrong, or the drugs were fake, or the doctor was untrained, or the patient had no money. Should this terrible reality preclude the need for continuous research to develop new antimalarial drugs? Should people working in laboratories located in non-endemic countries adapt their project to that reality? Malaria eradication, then elimination was announced and broadcasted in the late sixties, and later forgotten. From that failure due to chloroquine resistance and after decades of less arrogant work, billions of dollars are on the table again to claim this goal. There were bed nets, drugs, vaccine and communication as starters, let’s hope people in endemic countries will be winners.
Export Options
About this article
Cite this article as:
Picot Stephane, Loiseau M. Philippe and Bienvenu Anne-Lise, New Anti-Malarial Drugs: Who Cares?, Current Topics in Medicinal Chemistry 2014; 14 (14) . https://dx.doi.org/10.2174/1568026614666140808121039
DOI https://dx.doi.org/10.2174/1568026614666140808121039 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Status Epilepticus: An Overview
Current Drug Metabolism Colchicine in Coronary Artery Disease: An Old Acquaintance in New Attire?
Current Medicinal Chemistry Investigations on the Structural Characteristics that Seed the Aggregation of Amyloid-β<sub>1-42</sub> Peptide: Insights from Molecular Dynamics Simulations
Current Proteomics Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics A Novel Method to Synthesize Phosphocreatine and Phosphocreatine Prodrugs
Medicinal Chemistry Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism Challenges for Gene Therapy of Type 1 Diabetes
Current Gene Therapy Assessing Medication Problems in those ≥ 65 Using the STOPP and START Criteria
Current Aging Science Interactions Between Hypertension and Hypercholesterolemia: From Epidemiology to Therapeutic Implications
Current Hypertension Reviews A Mini-Review on Cardiovascular and Hematological Complications of COVID-19
Coronaviruses The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Editorial [Hot Topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Hypertension-Related Disorders (Executive Guest Editor: Aurelio Leone)]
Current Pharmaceutical Design Efficacy of Topical Formulations in Healing of Caesarean Scars Using Non-Invasive Devices: A Controlled Trial
Applied Drug Research, Clinical Trials and Regulatory Affairs The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis
Current Medicinal Chemistry Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences
Current Drug Delivery Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation
Current Vascular Pharmacology